Neonatal Encephalopathy: Biomarkers and Prognosis
Neonatal encephalopathy describes disturbed neurological function in the first days of life, often expressed through altered consciousness, abnormal tone, seizures, weak feeding, or impaired respiration. Hypoxic-ischaemic encephalopathy (HIE) is one important cause, but infection, metabolic disease, stroke, intracranial haemorrhage, and genetic conditions can produce similar early findings.
Prognosis depends on integrating several streams of evidence rather than relying on one laboratory value or examination. A newborn’s clinical grade, response to treatment, electroencephalography, magnetic resonance imaging, and evolving neurological function all contribute to a more reliable assessment. Biomarkers can strengthen that assessment, especially when early signs are difficult to interpret.
The subject reflects the collaborative focus of perinatal and neonatal medicine represented by the FAOPS 2020 congress archive, which was prepared for the Federation of Asian and Oceania Perinatal Societies meeting in Tokyo before the event was canceled in April 2020 because of the COVID-19 pandemic and international travel restrictions.
Why Early Assessment Matters
Neonatal encephalopathy is time-sensitive because the first hours after birth may determine access to neuroprotective treatment. Therapeutic hypothermia is generally considered for carefully selected infants with evidence of significant perinatal hypoxia-ischaemia, moderate or severe encephalopathy, and an appropriate gestational age and treatment window. Decisions must be made quickly, often before the full neurological picture has emerged.
Initial evaluation includes Apgar scores, cord or early blood-gas analysis, resuscitation history, neurological examination, glucose measurement, infection assessment, and screening for seizures. Low pH, raised lactate, and a substantial base deficit can indicate metabolic stress, but they do not independently establish brain injury or predict an individual child’s future.
Clinical staging systems help describe severity through consciousness, spontaneous activity, posture, tone, primitive reflexes, autonomic function, and seizures. Examinations can change rapidly, however, and sedatives, analgesics, magnesium exposure, respiratory illness, and cooling itself may alter findings. Repeated examinations are therefore more informative than a single early assessment.
What Biomarkers Can Reveal
Blood and cerebrospinal fluid biomarkers reflect different biological processes. Lactate and base deficit provide information about systemic anaerobic metabolism, while markers such as neuron-specific enolase (NSE), S100 calcium-binding protein B (S100B), glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase L1 (UCH-L1) are associated with neuronal or glial injury. Inflammatory mediators, including interleukin-6, may indicate immune activation after an insult.
A useful biomarker should be measurable at a clinically relevant time, show a reproducible relationship with injury severity, and add information beyond examination and neuroimaging. Many candidates perform well in research settings but are affected by sampling time, gestational age, renal clearance, haemolysis, laboratory technique, and the presence of extracerebral tissue injury. These variables can limit comparisons between hospitals and studies.
Research into prenatal diagnostics also illustrates the wider movement toward earlier, less invasive risk assessment. The discussion of prenatal testing advances is relevant to perinatal care, although prenatal screening and postnatal brain-injury biomarkers answer different clinical questions. A prenatal test may identify genetic or chromosomal risk, whereas neonatal biomarkers aim to describe an infant’s physiological response or tissue injury after birth.
EEG, MRI, and Bedside Monitoring
Amplitude-integrated EEG and conventional EEG provide functional information that a blood test cannot supply. Background suppression, burst-suppression patterns, sleep-wake cycling, and electrographic seizures can help identify infants at higher risk of adverse outcomes. Continuous EEG is especially important because many neonatal seizures have few or no visible clinical signs.
The timing of electrical recovery matters. A persistently severely abnormal background and recurrent electrographic seizures are concerning, while the development of organised sleep-wake cycling is generally a more reassuring sign. Antiseizure medicines, hypothermia, metabolic disturbances, and recording quality can influence interpretation, so EEG findings should be considered alongside the infant’s treatment history.
MRI, particularly diffusion-weighted imaging and magnetic resonance spectroscopy, provides structural and metabolic evidence of injury. Patterns involving the basal ganglia, thalami, perirolandic cortex, watershed regions, or white matter may carry different prognostic implications. Imaging can also reveal stroke, venous thrombosis, haemorrhage, or developmental abnormalities that would not be explained by presumed HIE.
MRI timing is important. Diffusion abnormalities may evolve over the first several days, and early scans can underestimate injury. A scan performed after the initial physiological changes have developed may offer greater prognostic value, but clinical instability can make transport and imaging unsafe. Neuroimaging should therefore be scheduled according to medical stability and the question clinicians need it to answer.
Building a Reliable Prognostic Picture
Prognosis should be framed as a probability that changes over time, rather than as an immediate fixed label. A severely abnormal early examination may improve, particularly after correction of hypoglycaemia, acidosis, respiratory failure, or medication effects. Conversely, subtle early signs can be followed by seizures or imaging findings that reveal more extensive injury.
The strongest assessment combines independent evidence. A persistently abnormal neurological examination, severe EEG background abnormality, extensive injury on MRI, and markedly abnormal biomarkers together create a more concerning pattern than any one result alone. Concordant reassuring findings can support cautious optimism, while discordant results should prompt observation, repeat testing, and specialist review.
Family communication is part of prognostic care. Clinicians should explain what is known, what remains uncertain, and when additional information is expected. Terms such as “risk of developmental impairment” are more accurate than absolute predictions in the early neonatal period. Outcomes may include motor disability, epilepsy, cognitive difficulties, language impairment, visual problems, or a normal developmental trajectory.
Long-term follow-up remains essential even when the newborn period appears reassuring. Standardised developmental assessment, hearing and vision checks, early intervention, and coordinated paediatric neurology care can identify difficulties early. Prognostic research should measure outcomes across childhood rather than treating survival or discharge from intensive care as sufficient endpoints.
Comparing Prognostic Tools
No single test captures the full effect of neonatal brain injury. The value of each method depends on timing, technical quality, and the clinical context in which it is interpreted.
| Assessment method | Main information provided | Useful timing | Important limitations | Typical clinical role |
|---|---|---|---|---|
| Neurological examination | Consciousness, tone, reflexes, seizures, autonomic function | Repeatedly from birth onward | Affected by medication, cooling, prematurity, and systemic illness | Determines encephalopathy severity and treatment eligibility |
| Cord or blood-gas analysis | Acidosis, lactate, and metabolic stress | At birth and during early stabilisation | Indicates physiological insult but not specific brain damage | Supports assessment of perinatal compromise |
| EEG or aEEG | Brain electrical background and electrographic seizures | Continuous or serial monitoring in the first days | Requires expertise; medicines and artefact affect readings | Detects seizures and tracks functional recovery |
| MRI with diffusion sequences | Location and extent of structural injury | Often after the first few days, when stable | Access, transport, sedation, and evolving lesions can limit use | Refines prognosis and identifies alternative diagnoses |
| Serum biomarkers | Neuronal, glial, inflammatory, or metabolic injury signals | Depends on the marker and serial sampling protocol | Thresholds and assays are not fully standardised | Adjunct to examination, EEG, and imaging |
| Neurodevelopmental follow-up | Functional outcome over time | Infancy through childhood | Cannot guide immediate treatment decisions | Measures real-world developmental consequences |
Biomarker panels may eventually improve precision by combining markers of neuronal injury, glial activation, inflammation, and energy failure. For now, many panels remain investigational, and thresholds validated in one population may not transfer directly to another. Differences in cooling protocols, laboratory platforms, gestational age, and outcome definitions can change apparent accuracy.
The practical aim is therefore multimodal prognostication: use the examination to describe function, EEG to assess ongoing electrical activity, MRI to map injury, laboratory results to identify systemic and biological stress, and follow-up to determine actual development. This approach reduces the risk of premature decisions based on an isolated abnormal result.
Applying Evidence in Neonatal Care
Clinical teams can make prognostic assessment more consistent by agreeing on when data will be collected, how it will be documented, and which findings require repetition. A structured pathway can include:
- Record the birth history, resuscitation details, cord gases, lactate, glucose, and serial neurological examinations.
- Start appropriate EEG monitoring early when encephalopathy or seizures are suspected.
- Use MRI and diffusion-weighted imaging when the infant is stable and the results are likely to clarify injury pattern or prognosis.
- Interpret biomarkers with attention to gestational age, sampling time, organ function, haemolysis, treatment, and laboratory method.
- Arrange developmental follow-up and communicate uncertainty clearly with the family.
Research priorities include harmonised biomarker assays, age-specific reference ranges, repeated sampling protocols, and outcome measures that extend into school age. Studies should also examine whether a biomarker changes management, rather than merely showing statistical association with an outcome. A clinically useful test must improve decisions, reduce uncertainty, or identify treatable secondary injury.
The field is moving toward precision neonatal neurology, where biological signals are combined with functional monitoring and long-term developmental data. This direction may support better selection for neuroprotective therapies, earlier recognition of seizures, and more individualised follow-up. It also reinforces the need for collaboration among obstetricians, neonatologists, neurologists, radiologists, laboratory scientists, therapists, and families.
Explore the FAOPS 2020 scientific resources and related perinatal research to place current work on neonatal encephalopathy within the wider development of fetal, newborn, and neonatal medicine. Continued study of biomarkers, EEG, MRI, and childhood outcomes will help transform early warning signals into more accurate and compassionate care.
